Eli Lilly Sues Synthon Pharmaceuticals for Patent Infringement

 Indianapolis, Indiana – Patent attorneys for Eli Lilly and Company of Indianapolis, IN, and its subsidiary ICOS Corporation of Indianapolis, IN, initiated litigation alleging Synthon Pharmaceuticals, Inc. of Research Triangle Park, NC, have infringed the following two patents, as issued by the US Patent Office: Patent No. 6,821,975, titled BETA-CARBOLINE DRUG PRODUCTS, and Patent No. 7,182,958, titled BETA.-CARBOLINE PHARMACEUTICAL COMPOSITIONS.

This lawsuit arose after the defendant filed an Abbreviated New Drug Application (“ANDA”) with the FDA seeking approval to market a generic version of the Lilly drug ADCIRCA(R) prior to the expiration of the ‘975 and ‘958 patents and despite Lilly holding approved New Drug Application No. 022332 for the same drug in a dosage identical to that in the defendant’s ANDA. The defendant contends that the Lilly patents are invalid, unenforceable, or would not be infringed by its product.

This case has been assigned to Judge Sarah Evans Barker and Judge Jane E. Magnus-Stinson in the Southern District of Indiana, and assigned case no. 1:10-cv-00310-SEB-JMS.

Practice Tip: A generic drug must be identical to a formerly-patented drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use; a company seeking approval to market a generic drug is required to file an ANDA.Complaint – Eli Lilly v. Synthon

Further information about this case is as follows:

Filed: March 15, 2010 as 1:2010cv00310 Updated: June 11, 2010 00:00:19



Presiding Judge: Judge Sarah Evans Barker

Referring Judge: Judge Jane Magnus-Stinson

Cause Of Action: Patent Infringement

Court: Seventh Circuit > Indiana > Southern District Court

Type: Intellectual Property > Patent

Contact Information